Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SanBio Co ( (JP:4592) ) just unveiled an announcement.
SanBio Co., Ltd. announced the publication of interim analysis results from a Phase 2 clinical trial of their SB623 product in the journal Neurotrauma Reports. The study examined the efficacy of stem cell transplantation in TBI patients, highlighting how the implantation site’s proximity to injury affects treatment outcomes. The results underscore the importance of tailoring surgical approaches in regenerative medicine, as advised by Japan’s Ministry of Health, Labour and Welfare, to enhance therapeutic outcomes.
More about SanBio Co
SanBio Co., Ltd. operates within the biotechnology industry, focusing on the development of regenerative medicine products. The company is engaged in the research and development of modified mesenchymal stem cells, particularly targeting treatments for traumatic brain injury (TBI).
Average Trading Volume: 1,635
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $447.4M
For an in-depth examination of 4592 stock, go to TipRanks’ Stock Analysis page.